P2RY14 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL182551	0.78	17/20
Uridine Diphosphate Glucose (SCHEMBL181055)	1.00	13/20
Uridine Diphosphate Glucose (SCHEMBL454078)	1.00	13/20
SCHEMBL478077	0.48	13/20
SCHEMBL692573	0.53	11/20
SCHEMBL478090	0.44	10/20
SCHEMBL478025	0.44	10/20
SCHEMBL432100	0.82	8/20
SCHEMBL113175	0.60	8/20
SCHEMBL111809	0.59	8/20
SCHEMBL41269	0.55	8/20
SCHEMBL366853	0.55	8/20
SCHEMBL182127	0.52	8/20
SCHEMBL182107	0.50	8/20
SCHEMBL27434	0.45	8/20
SCHEMBL478079	0.39	8/20
SCHEMBL478080	0.39	8/20
SCHEMBL477928	0.36	8/20
SCHEMBL478188	0.36	8/20
SCHEMBL478189	0.36	8/20

Clinical trials — most relevant to P2RY14 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
H2 Haplotype and CYP3As Polymorphisms and the Antiplatelet Response to Clopidogrel	PHASE4	COMPLETED
Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine	PHASE4	COMPLETED
Reversal of the Anti-platelet Effects of Ticagrelor	PHASE4	COMPLETED
Effect of Amlodipine on Anti-platelet Drug Effect in Patients With Coronary Artery Disease	PHASE4	COMPLETED
Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction (AMI) Patients According to CYP2C19 Polymorphism	PHASE4	COMPLETED
The Effect of IV Cangrelor and Oral Ticagrelor Study	PHASE4	COMPLETED
Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR	PHASE4	NOT_YET_RECRUITING
Efficacy of Ticagrelor vs Clopidogrel in High-risk NSTE-ACS Patients Undergoing Early PCI	PHASE4	UNKNOWN
Antiplatlet Effects of Standardized Tomato Extract in Hypertensive Subjects	PHASE4	COMPLETED
Add-on Cangrelor in STEMI-triggered Cardiac Arrest	PHASE4	UNKNOWN
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study	PHASE4	COMPLETED
Clopidogrel and Response Variability Investigation Study 2	PHASE3	COMPLETED
Ticagrelor And PrEconditioning in Patients With coronaRy Artery diSease	PHASE2/PHASE3	COMPLETED
Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention.	PHASE3	WITHDRAWN
Trimetazidine as an Adjunct to Enhance Clopidogrel Response.	PHASE2	COMPLETED
POPular GUILTY PILOT: Genotype-guided Clopidogrel Monotherapy	PHASE2	RECRUITING
Influence of CYP2C19 Genetic Variants on Clopidogrel in Healthy Subjects	PHASE1	COMPLETED
The Impact of Genotype on Pharmacokinetics and Antiplatelet Effects of Ticagrelor in Healthy Chinese	PHASE1	COMPLETED
First Time in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Effect of Food of Single Assending Doses of GSK1482160.	PHASE1	COMPLETED
Identification of Clopidogrel CYP2C19 Metabolizer and Thienopyridine Treatment After an Acute Coronary Syndrome	nan	COMPLETED
Genotyping GUided Antiplatelet theRapy in pAtieNts Treated With Drug Eluting stEnts (GUARANTEE)	nan	ACTIVE_NOT_RECRUITING
Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence	nan	COMPLETED
Suppressive Functions of Regulatory T Cells in Migraine	nan	NOT_YET_RECRUITING
Platelet Function in Resuscitated Patients	nan	COMPLETED
Impact of Ticagrelor Re-load on Pharmacodynamic Profiles	nan	COMPLETED
Diadenosine Polyphosphates and Mucin Associated With Ocular Surface Disorders	nan	UNKNOWN
Genetic Polymorphism Associated With Coronary Heart Disease Susceptibility and Variability of Clopidogrel Response	nan	ACTIVE_NOT_RECRUITING
Impact of Timing of PD Assessments on Measures of Platelet Reactivity in Patients Undergoing PCI Treated With Cangrelor	nan	COMPLETED
Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention	nan	COMPLETED
An Investigation Into the Mechanism of Inhalation Cough Challenge	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a P2RY14 binder may also engage these)

Protein	Name	Similarity
Q9ESG6	—	1.000	Q9ESG6 →
Q3SX17	—	1.000	Q3SX17 →
Q9CPV9	—	0.999	Q9CPV9 →
O35881	—	0.997	O35881 →
P2RY12	P2Y purinoceptor 12	0.992	landscape →
Q95KC3	—	0.991	Q95KC3 →
Q9EPX4	—	0.990	Q9EPX4 →
D4A4Q2	—	0.986	D4A4Q2 →
Q3ZBK9	—	0.985	Q3ZBK9 →
O14626	—	0.984	O14626 →
Q4G072	—	0.982	Q4G072 →
Q8BG55	—	0.982	Q8BG55 →
Q99MT7	—	0.979	Q99MT7 →
Q9BY21	—	0.979	Q9BY21 →
Q8BLG2	—	0.978	Q8BLG2 →
Q924T8	—	0.976	Q924T8 →
LPAR6	Lysophosphatidic acid receptor 6	0.976	landscape →
LPAR4	Lysophosphatidic acid receptor 4	0.976	landscape →
P32250	—	0.975	P32250 →
P55086	—	0.972	P55086 →
Q8BMC0	—	0.971	Q8BMC0 →
Q9R1K6	—	0.971	Q9R1K6 →
CYSLTR1	Cysteinyl leukotriene receptor 1	0.970	landscape →
Q2NNR5	—	0.969	Q2NNR5 →
Q924T9	—	0.969	Q924T9 →
Q95N02	—	0.967	Q95N02 →
F2RL1	Proteinase-activated receptor 2	0.967	landscape →
P60019	—	0.966	P60019 →
Q2HJA4	—	0.966	Q2HJA4 →
Q80Z39	—	0.966	Q80Z39 →